IGF-1 LR3
Long R3 IGF-1 · LR3-IGF-1
Popular for:Muscle protein synthesis, extended half-life IGF-1, anabolic
0
Registered Trials
0
Trial Publications
10
PubMed References
Animal
Evidence Level
Overview
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with an extended half-life of approximately 20-30 hours compared to minutes for native IGF-1. The short version: people usually care about it for muscle protein synthesis, extended half-life igf-1, anabolic, but the strength of the evidence depends heavily on indication and study type.
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with an extended half-life of approximately 20-30 hours compared to minutes for native IGF-1. The modifications include an arginine substitution at position 3 and a 13-amino acid extension at the N-terminus, which reduce binding to IGF binding proteins (IGFBPs).
IGF-1 is a critical mediator of growth hormone's anabolic effects. While GH triggers IGF-1 production in the liver, IGF-1 LR3 provides direct IGF-1 receptor activation with enhanced potency and duration. It is one of the most potent anabolic research compounds available.
Research Snapshot
What the evidence says
AnimalIGF-1 LR3 currently shows 0 registered trials from ClinicalTrials.gov, 0 PubMed trial publications (0 RCT-tagged), and 10 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 0 registered trials are tracked from ClinicalTrials.gov intervention records.
- 0 PubMed clinical-trial publications are indexed.
- 0 PubMed randomized controlled trial publications are indexed.
- 10 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
IGF-1 LR3 binds to IGF-1 receptors throughout the body, activating the PI3K/Akt signaling pathway which promotes protein synthesis, cell proliferation, and anti-apoptotic signaling.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
0
Registered Trials
0
Trial Publications
0
RCT Publications
10
PubMed References
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
0
Registered trials
0
Trial publications
0
RCT publications
10
PubMed references
0
Reviews
0
Meta-analyses
Registered trials source
Jun 1, 2026
IGF-1 LR3
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View sourceNot FDA-approved. Research compound. Related to FDA-approved mecasermin (Increlex) which is recombinant IGF-1 for growth failure. WADA prohibited substance. High regulatory scrutiny.
Key PubMed References
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.
Engel MG, Narayan S, Cui MH, et al. · Journal of Alzheimer's disease : JAD · 2025
PMID: 39610283Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.
Yavuz E, Sağır MS, Ercan A, et al. · International journal of biological macromolecules · 2025
PMID: 41015370IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.
White A, Stremming J, Wesolowski SR, et al. · American journal of physiology. Endocrinology and metabolism · 2025
PMID: 39679943Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.
White A, Stremming J, Brown LD, et al. · Journal of developmental origins of health and disease · 2023
PMID: 37114757Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris.
Lu Z, Liu N, Huang H, et al. · Applied microbiology and biotechnology · 2023
PMID: 37261455Anecdotes & Sentiment
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
No curated public-discussion themes are live for IGF-1 LR3 yet.
Side Effects & Safety
- Hypoglycemia (IGF-1 has insulin-like effects) - Joint pain and swelling - Potential organ growth with prolonged use - Theoretical cancer concerns (promotes cell proliferation) - Jaw and hand growth at high doses
Known Interactions
No curated interaction entry is live for IGF-1 LR3 yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.